Novo Nordisk Cuts Wegovy Price by 37% to Expand Obesity Treatment Access in India
Novo Nordisk India has slashed the price of its obesity treatment, Wegovy, by up to 37%. The move could significantly reshape the pricing dynamics in India's emerging obesity treatment segment, where competition with Eli Lilly is heating up.
The price reduction sees the starting dose of 0.25 mg drop from ₹4,336 to ₹2,712 per week. Vikrant Shrotriya, Managing Director of Novo Nordisk India, attributed the revision to the company's commitment to providing accessible, safe, and sustainable treatment for obesity. The new price aims to make Wegovy more affordable for the 254 million Indians with generalised obesity and 351 million with abdominal obesity, as per the ICMR-INDIAB study.
Doctors and analysts welcome the price cut, anticipating increased accessibility for patients. While the reduction may boost overall consumption, it might not immediately shift patient preference away from Eli Lilly's Mounjaro. The World Obesity Federation projects a tenfold increase in India's obesity-related healthcare costs by 2060, highlighting the urgent need for affordable treatment options.
Novo Nordisk's price reduction of Wegovy could transform India's obesity treatment landscape. With the new price, more Indians may access effective weight management and cardiovascular risk reduction. However, the impact on patient preference between Novo Nordisk and Eli Lilly remains to be seen.
